Hepatitis C Screening in Post–Baby Boomer Generation Americans: One Size Does Not Fit All
“For HCV elimination, passive “universal” screening in routine health care settings is insufficient, although the efficiency of screening may be improved with alanine aminotransferase prescreening. Importantly, for individuals with limited access to health care, proactive outreach programs for HCV screening are still needed.”

HCV-Infected Liver Transplant Patients Benefit from DAA Use, Study Finds
“Sustained virological response (SVR) was associated with improvements in hepatic function, liver fibrosis, and post-liver transplantation survival in a retrospective cohort study of HCV-infected liver transplant recipients who received direct-acting antiviral (DAA) treatment after liver transplantation.”

Implementing Better Standard Instruments for Detecting Cirrhosis in Hepatitis C Patients
“An increasing number of hepatitis C diagnoses in the younger population could partly be due to the rising opioid epidemic and intravenous drug use. Using hepatic venous portal gradient (HVPG) and liver stiffness tests, this study investigates better early diagnostic markers in identifying cirrhosis-related complications compared to percutaneous liver biopsy in hepatitis C patients.”

6 Drug Classes and Vaccine Candidates for Hepatitis C
“Hepatitis C virus (HCV) pharmacotherapeutic management is prominently led by the direct-acting antiviral (DAA) drug class, a staple of viral mitigation in patients for the last decade now. However, advances in treatment diversity and potential prevention are still pursued—despite DAAs’ significant efficacy.”

Vosevi Is Effective for Retreatment of Hepatitis C
“Most people with hepatitis C virus (HCV) can be successfully treated with Vosevi (sofosbuvir/velpatasvir/voxilaprevir) after a previous treatment failure, according to study findings published in the Journal of Hepatology. Adding ribavirin to the regimen made little difference in efficacy but led to more adverse events.”